- About us
- Clinical Trials
- News & Publications
- Business Development
SOTIO® DCVAC is an investigational medicinal product line based on a new active cellular immunotherapy platform. SOTIO uses the SOTIO® DCVAC platform to develop three product candidates for different cancers in various stages: DCVAC/PCa for patients with prostate cancer, DCVAC/OvCa for patients with ovarian cancer and DCVAC/LuCa for patients with lung cancer. We are currently testing the safety and efficacy of investigational medicinal treatment DCVAC through multiple Phase I to Phase III clinical trials. For more information about SOTIO DCVAC, please see the section DCVAC Technology.
DCVAC/PCa Product is an autologous immunotherapy, which is currently in a global Phase III clinical trial VIABLE study (http://www.viablestudy.com/) for the treatment of patients with metastatic castrate resistant prostate cancer and in multi-center Phase II clinical trials for the treatment of patients with prostate cancer at various stages - read more
DCVAC/OvCa Product is an autologous immunotherapy, which is currently in Phase II clinical trials in combination with the standard of care treatments in patients with epithelial ovarian cancer - read more
DCVAC/LuCa Product is an autologous immunotherapy, which is currently in a Phase I/II clinical trial focused on the treatment for patients with advanced metastatic non-small cell lung carcinoma (NSCLC) - read more